Oct 2018;41:113-132
Phase 2 Obesity Trial (N=338) The key phase 2 randomized controlled trial published in the New England Journal of Medicine enrolled 338 adults with obesity (BMI 30 to 50 kg/m) and randomized them to once-weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, versus placebo over 48 weeks [5]
IGF-1 also inhibits protein breakdown by downregulating the expression of genes involved in muscle atrophy, such as MuRF1 and MAFbx (Lai et al., 2004)
Zepbound (tirzepatide) is approved for chronic weight management in adults with obesity or overweight with a weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity
Treatment of mice with DS-induced colitis (resembling human ulcerative colitis) with the human GLP-2 analog h(Gly 2 )GLP, twice daily for 10 days, reverses weight loss independent on food intake, decreases interleukin-1 expression and increased colon length, crypt depth, and mucosal area compared to treatment with saline (Drucker et al., 1999)
